Our mission is to revolutionize disease treatment for patients worldwide with small molecule therapeutics that modify RNA expression
Skyhawk’s potent small molecule drug candidates target RNA across a broad range of neurodegenerative and other challenging diseases
Health care professionals, media, investors, or patients please use the inquiry form to contact us for further information on our pipeline and programs.
